Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2012

Nov 14, 2012

30016_dirs_2012-11-14_c50ac5ba-ac1e-4f92-8b5c-5b12d605ce90.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2012-11-12

Reporting Person: Williams Michael J PhD (Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-11-12 Common Stock M 12449 $34.37 Acquired 19914 Direct
2012-11-12 Common Stock M 2500 $28.6550 Acquired 22414 Direct
2012-11-12 Common Stock M 1294 $28.6550 Acquired 23708 Direct
2012-11-12 Common Stock S 12449 $89.1335 Disposed 11259 Direct
2012-11-12 Common Stock S 1294 $89.1585 Disposed 9965 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-11-12 Non-Qualified Stock Option (right to buy) $34.37 M 12449 Disposed 2016-02-13 Common Stock (12449) Direct
2012-11-12 Incentive Stock Option $28.6550 M 2500 Disposed 2015-02-02 Common Stock (2500) Direct
2012-11-12 Incentive Stock Option $28.6550 M 1294 Disposed 2015-02-02 Common Stock (1294) Direct

Footnotes

F1: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $89.00 to $89.59, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2 to this Form 4.

F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $89.15 to $89.16, inclusive.

F3: Grant of options to buy shares of common stock becomes exercisable as to 4,149 shares on 02/14/2010, 4,150 shares on 02/14/2011, 4,150 shares on 02/14/2012, 4,149 shares on 02/14/2013, and the remaining 1,241 shares on 02/14/2014.

F4: Grant of options to buy shares of common stock becomes exercisable as to 1,074 shares on 02/03/2009 and the remaining 2,720 shares on 02/03/2010.